13 completed, 1 unknown. 8 Phase 3, 4 Phase 4, 1 Not applicable, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 8 | Completed 8 |
| Phase 4 | 4 | Completed 3, Unknown 1 |
| Not applicable | 1 | Completed 1 |
| Phase 2 | 1 | Completed 1 |
Follow Levomilnacipran: new trials by email Literature Review of Levomilnacipran trials Research Report on Levomilnacipran
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy, Safety, and Tolerability of Levomilnacipran ER in Pediatric Patients (7-17 Years) With Major Depressive Disorder Levomilnacipran ER, Fluoxetine, Placebo - Major Depressive Disorder | Phase 3 | Completed | Allergan | 501 | 2018-07-06 | 2022-03-25 |
| Levomilnacipran in Healthy Males Levomilnacipran, Duloxetine, Placebos - None (i.e. Healthy Volunteers) | Phase 4 | Unknown | University of Ottawa | 36 | 2018-03-02 | 2021-10-06 |
| Neural Mechanisms of Monoaminergic Engagement in Late-life Depression Treatment Response (NEMO) Escitalopram Pill, Placebo, Levomilnacipran Pill - Major Depressive Disorder | Phase 4 | Completed | Howard Aizenstein | 57 | 2017-05-24 | 2025-03-10 |
| Levomilnacipran ER vs. Adjunctive Quetiapine for Adults With Inadequate Relief With SSRIs in MDD Levomilnacipran, Quetiapine - Major Depressive Disorder | Phase 3 | Completed | Duke University | 60 | 2017-01-23 | 2019-08-14 |
| Trial of Levomilnacipran in Geriatric Depression levomilnacipran, Placebo - Major Depressive Disorder | Phase 4 | Completed | University of California, Los Angeles | 29 | 2016-06-01 | 2019-08-14 |
| Safety and Efficacy of Levomilnacipran ER in Adolescent Participants With Major Depressive Disorder Placebo, Levomilnacipran, Fluoxetine - Major Depressive Disorder | Phase 3 | Completed | Forest Laboratories | 552 | 2015-06-23 | 2020-09-07 |
| Novel Medication as a Potential Smoking Cessation Aid Levomilnacipran, Placebo - Tobacco Use Disorder | Not applicable | Completed | University of Minnesota | 56 | 2015-01-01 | 2022-04-22 |
| A Multicenter, Relapse Prevention Study With Levomilnacipran Extended Release (ER) in Participants With Major Depressive Disorder Levomilnacipran ER, Placebo - Depressive Disorder, Major | Phase 4 | Completed | Forest Laboratories | 644 | 2014-11-18 | 2018-10-29 |
| Safety and Efficacy of Levomilnacipran ER (Levomilnacipran SR) in Major Depressive Disorder Levomilnacipran ER, Placebo - Major Depressive Disorder | Phase 3 | Completed | Forest Laboratories | 568 | 2011-06-01 | 2013-10-29 |
| Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Adults With Fatigue Associated With Major Depressive Disorder Levomilnacipran ER, Paroxetine, Sertraline, Citalopram or Fluoxetine., Placebo - Major Depressive Disorder | Phase 2 | Completed | Forest Laboratories | 262 | 2011-04-01 | 2014-08-06 |
| Relapse-Prevention Study With Levomilnacipran ER (F2695 SR) in Patients With Major Depressive Disorder Levomilnacipran ER, Placebo - Depression, Major Depressive Disorder | Phase 3 | Completed | Forest Laboratories | 734 | 2010-03-01 | 2020-01-13 |
| Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder Levomilnacipran ER, Placebo - Major Depressive Disorder | Phase 3 | Completed | Forest Laboratories | 442 | 2009-12-01 | 2013-10-25 |
| Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder Levomilnacipran ER, Placebo - Major Depressive Disorder | Phase 3 | Completed | Forest Laboratories | 362 | 2009-09-01 | 2013-10-25 |
| Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder Levomilnacipran ER, Placebo - Major Depressive Disorder | Phase 3 | Completed | Forest Laboratories | 724 | 2009-09-01 | 2013-10-25 |
Depressive Disorder, Major (12) · Depression (8) · Consciousness Disorders (1) · Fatigue (1) · Tobacco Use Disorder (1)
Forest Laboratories (8) · Allergan (1) · Duke University (1) · Howard Aizenstein (1) · University of California, Los Angeles (1) · University of Minnesota (1) · University of Ottawa (1)
United States (13) · Canada (3) · Puerto Rico (1)
Carl Gommoll, MS (5) · Ashwin A Patkar, MD (1) · Carmen Andreescu, MD (1) · Daniel Radecki (1) · Daniel Radecki, PhD (1) · Giovanna Forero, MA (1) · Helen Lavretsky, M.D. (1) · Howard J Aizenstein, MD, Ph.D. (1) · Michael Kotlyar, PharmD (1) · Pierre Blier, MD (1) · Raffaele Migliore (1)
PMID 26644957, PMID 38700708, PMID 23561229, PMID 24144196, PMID 24172209, PMID 25259674, PMID 27536449, PMID 27861191, PMID 31332902, PMID 33757609, PMID 40875503
R01MH076079 (1)